Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01256762 · ClinicalTrials.gov registry record · Phase 2
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
A Phase 2 study of Locally Recurrent or Metastatic Breast Cancer, sponsored by Geron Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 166
- Enrollment target
- 20
- Study locations
NCT01256762 is a Phase 2 study of Locally Recurrent or Metastatic Breast Cancer that has completed, run by Geron Corporation. The registered enrollment target is 166 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT01256762, a Phase 2 study of Locally Recurrent or Metastatic Breast Cancer, has completed, sponsored by Geron Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 166 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of treatment with imetelstat + paclitaxel (with or without bevacizumab) versus paclitaxel (with or without bevacizumab) alone for patients with locally recurrent or metastatic breast cancer who have not received chemotherapy or have received one non-taxane based chemotherapy for metastatic breast cancer.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Paclitaxel
- DRUG Imetelstat sodium
Study Locations (20)
California
- Alta Bates Summit Medical Center - Berkeley
- Southbay Oncology Hematology Partners - Campbell
- Cancer Care Associates - Fresno
- Memorial Miller Hospital - Long Beach
- St. Joseph Hospital - Orange
- Desert Regional Comprehensive Cancer Center - Palm Springs
- UC San Diego - San Diego
- Redwood Regional Medical Group - Santa Rosa
Georgia
- Northeast Georgia Cancer Care - Athens
- Peachtree Hematology Oncology - Atlanta
- Emory University - Atlanta
- Northeast Georgia Medical Center - Gainesville
- Central Georgia Cancer Care - Macon
Florida
- Florida Oncology Associates - Jacksonville
- Hematology Oncology Associates - Port Saint Lucie
- H. Lee Moffitt Cancer Center - Tampa
Connecticut
- Connecticut Oncology & Hematology - Torrington
- Medical Oncology Hematology - Waterbury
Alabama
- Clearview Cancer Center - Huntsville
Colorado
- Univ. Colorado at Denver - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2010-11 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01256762
The ClinicalTrials.gov registry entry for NCT01256762 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Geron Corporation, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Recurrent or Metastatic Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT01256762 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Georgia, Florida.
Frequently Asked Questions
What is clinical trial NCT01256762 about?
NCT01256762 is a clinical study titled "Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer". The purpose of this study is to evaluate the efficacy and safety of treatment with imetelstat + paclitaxel (with or without bevacizumab) versus paclitaxel (with or without bevacizumab) alone for patients with locally recurrent or metastatic breast cancer who have not received chemotherapy or have re...
What is the current status of trial NCT01256762?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 166 participants. The study started on 2010-11. Estimated completion is 2012-12.
What conditions does trial NCT01256762 study?
This clinical trial studies the following conditions: Locally Recurrent or Metastatic Breast Cancer.
What interventions are being tested in trial NCT01256762?
The interventions under investigation include: Bevacizumab (DRUG), Paclitaxel (DRUG), Imetelstat sodium (DRUG).
Who is sponsoring clinical trial NCT01256762?
This trial is sponsored by Geron Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01256762 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.